Assembly Biosciences, Inc. filings document a clinical-stage antiviral developer with common stock listed on the Nasdaq Global Select Market under ASMB. Recent 8-K reports furnish operating results and pipeline updates tied to investigational programs for recurrent genital herpes, chronic hepatitis delta virus and chronic hepatitis B virus, including disclosures on ABI-5366, ABI-1179, ABI-6250 and ABI-4334.
The filing record also covers the company’s collaboration revenue with Gilead, material definitive agreements, registered equity and warrant offerings, and securities registered under Section 12(b). Proxy and compensation-related filings describe governance, executive compensation, equity awards and performance-based cash bonus arrangements.
Assembly Biosciences, Inc. has adopted a new 2026 Corporate Bonus Plan, effective January 1, 2026, to motivate, retain, attract and reward employees using performance-based cash bonuses for results achieved between January 1 and December 31 each year.
Bonuses will be based on Company-wide “Corporate Objectives” and individual or team “Individual Objectives,” with weightings that vary by level, from 100% corporate for the CEO to 25% corporate and 75% individual for associate director and below. Target bonus opportunities range up to 75% of base salary for the CEO, 30%–55% for other executives and up to 28% for non-executives, with actual payouts ranging from 0 to 1.5 times the target. The Compensation Committee also increased CEO Jason A. Okazaki’s bonus target from 60% to 65% of base salary for fiscal 2026.
Assembly Biosciences, Inc. registered securities for an aggregate offering price of $400,000,000 under a shelf prospectus, and the related prospectus supplement covers up to $100,000,000 of common stock to be sold on an at-the-market basis.
The prospectus describes the types of securities that may be offered — common stock, preferred stock, debt securities, warrants, subscription rights and units — and states that specific terms will be provided in prospectus supplements. The supplement establishes an Open Market Sale Agreement with Jefferies LLC as sales agent for the $100,000,000 ATM program, and reports a last reported Nasdaq sale price of $27.52 per share as of March 18, 2026.
Assembly Biosciences, Inc. is a clinical-stage biotechnology company focused on next-generation antiviral drugs for serious viral diseases, including recurrent genital herpes, hepatitis B and D, and transplant-associated herpesviruses. Its pipeline features two long-acting helicase-primase inhibitors (5366 and 1179), an oral HDV entry inhibitor (6250), a next-generation HBV capsid assembly modulator (4334) and a broad-spectrum NNPI (7272).
In 2025 the company reported multiple positive Phase 1 data readouts across 5366, 1179, 4334 and 6250, generally showing strong antiviral activity, pharmacokinetics supporting convenient oral dosing and favorable safety profiles. Gilead Sciences exercised its option in December 2025 to exclusively license the HPI program, paying $35 million and taking over global development and commercialization, while Assembly remains eligible for up to $330 million in milestones plus tiered royalties and may later elect a 40% U.S. profit-share.
Assembly retains full control of 4334 after Gilead declined its option in March 2026 and is seeking a partner before advancing that HBV program. For HDV, Phase 2 initiation of 6250 is targeted for the fourth quarter of 2026. As of March 13, 2026, Assembly had 15,862,705 shares of common stock outstanding, and the aggregate market value of non-affiliate voting stock was $97.8 million as of June 30, 2025.
Assembly Biosciences reported sharply improved 2025 results, driven by its virology collaboration with Gilead. Collaboration revenue rose to $72.3M from $28.5M, while net loss narrowed to $6.1M, or $0.55 per share, from $40.2M in 2024.
Cash, cash equivalents and marketable securities increased to $248.1M as of December 31, 2025, supporting operations into 2028. The company received a net $35M option fee as Gilead licensed its helicase-primase inhibitor program, though Gilead declined its option on HBV candidate ABI‑4334. Assembly plans a potential U.S. cost-profit share election on the herpes program by mid‑2026 and aims to start Phase 2 for HDV candidate ABI‑6250 by the end of 2026.
Assembly Biosciences, Inc. is the subject of an amended Schedule 13G filing by a group of Farallon-managed investment funds and related entities. As of the date requiring this filing, the Farallon Funds together hold 1,227,590 Shares of Assembly Biosciences common stock.
The group also holds 510,205 Class A Warrants and 510,205 Class B Warrants, each currently treated as not exercisable for beneficial ownership purposes because of a 4.99% Beneficial Ownership Limitation and, for the Class B Warrants, an exercise date beginning on November 15, 2026. Certain Farallon entities and individual managers report beneficial ownership of up to 7.8% of the class.
This amendment mainly updates who is deemed a beneficial owner. Effective January 1, 2026, Avner A. Husen became a member or manager of the Farallon general partners and may be deemed a beneficial owner, while, effective December 31, 2025, Richard B. Fried, Rajiv A. Patel and William Seybold ceased those roles and may no longer be deemed beneficial owners. The reporting group certifies that the securities are not held for the purpose of changing or influencing control of Assembly Biosciences.
Assembly Biosciences, Inc. is registering up to 6,980,811 shares of common stock for resale by a selling stockholder. The prospectus covers an offering and resale from time to time by Gilead Sciences, Inc. and its permitted transferees, under a shelf registration, and Assembly will not sell any shares itself under this document.
The shares include stock Gilead previously acquired under several purchase agreements, as well as shares issuable upon exercise of related warrants. Because this is a secondary offering, any sale proceeds will go to the selling stockholder, while Assembly will cover registration and related listing expenses.
Assembly is a biotechnology company focused on therapies for serious viral diseases, including clinical‑stage programs in recurrent genital herpes, hepatitis B and delta viruses, and transplant‑related herpesviruses. Its common stock trades on the Nasdaq Global Select Market under the symbol ASMB, and the last reported sale price was $36.73 per share on November 20, 2025. Investors are directed to detailed risk factors incorporated by reference.
Assembly Biosciences (ASMB) reported Q3 results and strengthened its balance sheet. Collaboration revenue was $10,789 thousand, up from $6,845 thousand a year ago. Operating expenses were $21,672 thousand, leading to a net loss of $9,196 thousand, or $0.72 per share. For the nine months, collaboration revenue reached $29,834 thousand and net loss was $28,212 thousand.
Liquidity improved materially. In August 2025, the company raised gross proceeds of $175.0 million through an underwritten offering and a concurrent private placement. As of September 30, 2025, cash, cash equivalents and marketable securities totaled $232.6 million. Management states these funds meet operating requirements beyond one year, resolving prior going concern conditions. Deferred revenue from a related party was $44,078 thousand, supporting ongoing program funding. Shares outstanding were 15,816,987 as of September 30, 2025; as of November 7, 2025, there were 15,817,140 shares outstanding.
Pipeline execution continued with multiple Phase 1 programs, and Gilead-related collaboration revenue and accounts receivable of $912 thousand reflected active cost sharing under the agreement.
Assembly Biosciences, Inc. filed a current report to share that it has released its financial results for the quarter ended September 30, 2025. On November 10, 2025, the company issued a press release describing these quarterly results, which is included with the report as Exhibit 99.1. The company notes that this press release is being furnished under the results of operations and financial condition disclosure rules, rather than being formally filed under those provisions.